Pneumococcal Vaccine Response in Adults with Splenic Injury Comparing Nonoperative, Embolization, and Splenectomy Treatments

What this Trial Is About

Researchers are studying how the immune system responds to pneumococcal vaccination in adults who have suffered injuries to their spleen. These patients are vulnerable to serious infections, especially from pneumococcus bacteria. The study aims to compare antibody responses following different treatments for splenic injury, including nonoperative management, splenic artery embolization, and removal of the spleen splenectomy. Participants receive the Pneumovax-23 vaccine at different times depending on their treatment group within 72 hours after injury for nonoperative cases, and 14 days after either embolization or splenectomy. Blood samples are taken at vaccination and again four weeks later to measure levels of antibodies against pneumococcal bacteria. Imaging and other evaluations are used to assess the spleens condition after embolization. During the study, participants have blood drawn to analyze antibody levels using specific laboratory tests. Those treated with embolization undergo a CT scan three to five days after the procedure to assess spleen viability. Researchers measure changes in antibody levels and compare them with factors like treatment type and spleen condition. The study expects to last until July 2026, with careful monitoring throughout the process.

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients